Cosette Pharmaceuticals, Inc. has officially terminated its proposed AUD 7.40-per-share acquisition of Mayne Pharma Group Limited after the Australian government blocked the transaction. The decision was confirmed on December 9, 2025, and followed by Mayne Pharma’s own termination notice issued on December 11. The companies cited both the Treasurer of Australia’s ruling and the expiry of their Scheme Implementation Deed as reasons for walking away from the USD 430 million agreement, originally framed as a transformative leap for Cosette’s women’s health and dermatology footprint.

Australia’s foreign investment veto raises new questions for mid-cap healthcare deals

The Australian Treasurer’s intervention has exposed an underappreciated vulnerability in mid-sized pharma M&A: the unpredictable nature of cross-border regulatory scrutiny, even in sectors typically seen as less geopolitically sensitive. While the government has not publicly detailed its rationale, the decision to block the Cosette–Mayne transaction places pharmaceutical manufacturing and health-related assets under the same regulatory lens previously reserved for critical infrastructure and energy.

Industry observers suggest that concerns may have centered on potential job losses, offshoring of intellectual property, or loss of domestic manufacturing capacity. Mayne Pharma operates a TGA-approved manufacturing facility in South Australia, and the company holds several products that support national health priorities in women’s care. These factors likely contributed to heightened regulatory sensitivity.

Legal analysts note that the Treasurer’s rejection may set a precedent for closer scrutiny of pharma transactions under the Foreign Acquisitions and Takeovers Act. Although Australia’s Foreign Investment Review Board (FIRB) traditionally assessed deals on a case-by-case basis, the Cosette decision could trigger more conservative interpretations moving forward, particularly when the target owns manufacturing assets, proprietary formulations, or regulatory licenses seen as strategic.

Cosette Pharmaceuticals faces a strategic setback and potential litigation drag

Cosette Pharmaceuticals had framed the Mayne Pharma deal as a cornerstone of its aggressive expansion strategy. The acquisition promised to boost its U.S. leadership in women’s health and dermatology, integrating Mayne Pharma’s patent-protected portfolio with Cosette’s fast-growing brands including Vyleesi, Intrarosa, and Clomid. By absorbing Mayne’s complementary brands like Nextstellis, Bijuva, and Annovera, Cosette aimed to control one of the most differentiated specialty pharma portfolios in women’s care.

The collapse of the deal now leaves a vacuum in Cosette’s portfolio expansion roadmap. Analysts tracking specialty pharma consolidation warn that the disruption could delay pipeline growth and leave Cosette exposed to intensified competition from players like Organon and TherapeuticsMD. The company’s promise of dual-site manufacturing across Lincolnton, North Carolina and Salisbury, South Australia will not materialize, and its broader strategy of international scale-up through in-market acquisitions now faces greater risk.

Compounding the strategic fallout is the growing legal confrontation. Cosette has denied Mayne Pharma’s allegations of breach and plans to appeal an adverse ruling from the Supreme Court of New South Wales. It has also signaled its intent to pursue damages for what it claims was harm caused by Mayne’s conduct. While legal observers believe such claims may be hard to quantify, any litigation could become a prolonged distraction and inject additional risk into Cosette’s licensing and deal-making prospects in 2026.

Mayne Pharma’s independent future looks increasingly uncertain

For Mayne Pharma, the failed acquisition reverses what had been framed as a high-premium, high-certainty exit strategy. The company’s board had unanimously recommended the Cosette offer in February 2025, touting it as a strong value proposition for shareholders. The AUD 7.40 per share offer represented a significant uplift to Mayne’s pre-deal trading price, and the transaction had been positioned as a gateway to expanded innovation, access, and commercial reach.

With the deal off, Mayne Pharma must now reorient its business toward organic growth while dealing with the reputational and investor confidence fallout. The company still maintains a sizable commercial footprint in women’s health and dermatology, and its Australian manufacturing capabilities remain valuable. However, sector analysts note that the sudden reversal leaves Mayne exposed to potential staff attrition, commercial partner unease, and limited near-term access to capital.

Mayne Pharma’s dual termination notice and public allegations of Cosette’s breach suggest that the company is also preparing to mount a legal defense or counterclaim, depending on how Cosette proceeds. This mutual legal posturing could complicate future strategic conversations with other suitors or commercial collaborators. Investors are likely to press management on its standalone strategy during upcoming ASX disclosures.

Broader dealmaking implications: Regulatory risk joins valuation and synergy as top-tier diligence factors

Beyond the immediate fallout, the Cosette–Mayne Pharma failure signals a structural shift in how global pharmaceutical companies will approach M&A. In recent years, strategic rationale, product overlap, and manufacturing synergy dominated boardroom calculus. Now, cross-border regulatory feasibility is emerging as an equally critical determinant.

The inclusion of mid-cap pharma companies like Mayne Pharma under the umbrella of foreign investment controls could lead to new risk models for M&A bankers and corporate development teams. Legal advisors may begin advocating for more aggressive pre-deal engagements with foreign investment regulators and contingency clauses for adverse rulings. Deal structures might evolve to include staggered closings, geographic asset ringfencing, or fallback options in case of national interest objections.

This case also highlights how the regulatory definition of “strategic asset” is becoming more elastic. Governments previously focused on telecom, energy, and defense now appear to be applying similar scrutiny to pharmaceutical assets when they involve domestic production, women’s health, or pandemic preparedness.

The road ahead: Can Cosette and Mayne regain momentum?

Cosette Pharmaceuticals has stated that it remains committed to its business transformation, supported by a robust R&D and business development pipeline. While it retains a strong portfolio of more than 100 marketed products and operates a modern facility in North Carolina, its failed bid to scale through acquisition now leaves it more dependent on organic growth and smaller bolt-on deals.

The company’s response to this setback will likely define its 2026 strategy. Re-entering the M&A market may be difficult in the short term, particularly if litigation with Mayne Pharma escalates or reputational concerns persist among potential targets.

Mayne Pharma, meanwhile, must convince shareholders that a standalone growth story is still intact. The company continues to own several differentiated brands and a sales infrastructure that had been considered a key asset by Cosette. However, questions remain about its longer-term positioning, especially in a market where scale and integrated manufacturing are increasingly important.

Institutional investors, regulatory experts, and M&A observers alike will be closely watching how both firms handle the aftermath. If litigation intensifies or if new suitors emerge for Mayne Pharma, the story could evolve again in unexpected ways. For now, the terminated Cosette–Mayne deal stands as a stark reminder that even well-aligned cross-border acquisitions can unravel under the weight of regulatory risk and strategic missteps.

  Australia regulatory risk, Cosette Pharmaceuticals, cross-border acquisitions, dermatology, Foreign Investment Review Board, Mayne Pharma Group Limited, pharma M&A, women’s health